[ad_1]
Radnor, Pennsylvania, December 5, 2021 /PRNewswire/ – Law Firm Kessler Topaz Meltzer & Check, LLP Notify investors that they have filed against Novavax, Inc. (“Novavax”) (NASDAQ stock code:NVAX). The lawsuit alleges that Novavax violated federal securities laws, including omissions and fraudulent misrepresentations related to the company’s business, operations, and prospects. Due to Novavax’s material misleading statement, Novavax investors suffered significant losses.
Can’t watch this video?Please click here
click here Submit your NOVAAX loss
Deadline for lead plaintiff: January 11, 2022
class time: March 2, 2021 pass through October 19, 2021
Contact a lawyer to discuss your rights:
James Marlow, Esq. (484) 270-1453 or free (844) 887-9500 or email to info@ktmc.com
Novax Suspected misconduct
Novavax is a biotechnology company that develops vaccines for serious infectious diseases, including the vaccine NVX-CoV2373 developed for COVID-19. Before March 2021, Novavax announced that it plans to complete the emergency use authorization (“EUA”) of NVX-CoV2373 and submit it to the U.S. Food and Drug Administration (“FDA”) in the second quarter of 2021.
exist March 2, 2021, Novavax issued a press release stating that the company may submit the EUA in the second quarter of 2021, and the NVX-CoV2373 distribution plan and the agreement for approximately 200 million doses of NVX-CoV2373 have been completed and approved.Then, in May 10, 2021, Washington post According to the report, Novavax’s EUA “application was delayed due to manufacturing regulatory issues. According to four people who recently learned of the company’s plans, it would be June at the earliest.” Later that day, Novavax attended…
The full story can be found on Benzinga.com
[ad_2]
Source link
